Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 10, 2024American Journal of HematologyOpen Access

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SDSosana DelimpasiEvangelismos HospitalMeletios Α. DimopoulosMeletios Α. DimopoulosAlexandra HospitalJŠJan ŠtraubCharles University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Delimpasi et al. (2024) studied this question.

synapsesocial.com/papers/68e6566db6db6435875e5200https://doi.org/10.1002/ajh.27382
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Home visits: a strategy to improve newborn survival - Authors' reply2008 · 22,617 citations
  2. 2Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma2016 · 1,070 citations
  3. 3Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study2015 · 4 citations
  4. 4In Multiple Myeloma Progression Free and Overall Survival in the Relapsed Setting Remains Poor with Early Exposure to Novel Agents: Experience from a Real-World Cohort2015 · 3 citations